{
  "resourceType": "ResearchStudy",
  "id": "H2Q-MC-LZZT-ResearchStudy",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>identifier</b>: id: H2Q-MC-LZZT (USUAL), id: NCTA12313212 (OFFICIAL), PLAC: NCTA12313212 (SECONDARY)</p><p><b>title</b>: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>protocol</b>: <a href=\"PlanDefinition-LZZT-Study-Definition.html\">Generated Summary: url: http://example.org/br-and-r/soa/PlanDefinition/LZZT-Study-Definition; version: 0.1.0; status: active; date: Apr 9, 2021, 11:42:58 AM</a></p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: <span title=\"Codes: \">treatment</span></p><p><b>phase</b>: <span title=\"Codes: \">phase-3</span></p><p><b>category</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C98388}\">Interventional Study</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C15417}\">Randomized Clinical Trial</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C15228}\">Double Blind Study</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C49648}\">Placebo Control</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C82639}\">Parallel Study</span></p><p><b>focus</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C152926}\">Xanomeline</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C149996}\">Transdermal Patch Dosage Form</span></p><p><b>condition</b>: <span title=\"Codes: {http://snomed.info/sct 26929004}\">Alzheimer's Disease (Disorder)</span>, <span title=\"Codes: {http://snomed.info/sct G30}\">Alzheimer's disease</span>, <span title=\"Codes: {http://snomed.info/sct 10001896}\">Alzheimer's disease</span></p><p><b>contact</b>: Bob James, Ph.D.: ph: 555-555-5555(WORK)</p><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td>-</td></tr><tr><td>*</td></tr></table><p><b>keyword</b>: <span title=\"Codes: {https://id.nlm.nih.gov/mesh D018721}\">Selective M1 muscarinic agonists</span></p><p><b>description</b>: # Xanomeline (LY246708)\n# Protocol H2Q-MC-LZZT(c) \nSafety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>sponsor</b>: <a href=\"Organization-EliLillyAndCompany.html\">Generated Summary: id: Eli Lilly and Company (OFFICIAL); <span title=\"Codes: \">crs</span></a></p><p><b>principalInvestigator</b>: <a href=\"Practitioner-SamGetWell.html\">Generated Summary: UPIN: ABC123 (OFFICIAL); active; Samuel Home ; Phone: 555-123-5467; gender: male</a></p><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C49648}\">C49648</span></p><p><b>description</b>: Placebo arm</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Low-dose xanomeline arm</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C174266}\">C174266</span></p><p><b>description</b>: Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: High-dose xanomeline arm</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C174266}\">C174266</span></p><p><b>description</b>: High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p><p><b>type</b>: <span title=\"Codes: \">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To document the safety profile of the xanomeline TTS.</p><p><b>type</b>: <span title=\"Codes: \">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the treatment response as a function of Apo E genotype.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote></div>"
  },
  "identifier": [
    {
      "use": "usual",
      "value": "H2Q-MC-LZZT"
    },
    {
      "use": "official",
      "system": "https://clinicaltrials.gov/show/",
      "value": "NCTA12313212"
    },
    {
      "use": "secondary",
      "type": {
        "coding": [
          {
            "code": "PLAC"
          }
        ]
      },
      "value": "NCTA12313212"
    }
  ],
  "title": "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease",
  "protocol": [
    {
      "reference": "PlanDefinition/LZZT-Study-Definition"
    }
  ],
  "status": "completed",
  "primaryPurposeType": {
    "coding": [
      {
        "code": "treatment"
      }
    ]
  },
  "phase": {
    "coding": [
      {
        "code": "phase-3"
      }
    ]
  },
  "category": [
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C98388",
          "display": "Interventional Study"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C15417",
          "display": "Randomized Clinical Trial"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C15228",
          "display": "Double Blind Study"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C49648",
          "display": "Placebo Control"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C82639",
          "display": "Parallel Study"
        }
      ]
    }
  ],
  "focus": [
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C152926",
          "display": "Xanomeline"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://ncimeta.nci.nih.gov",
          "code": "C149996",
          "display": "Transdermal Patch Dosage Form"
        }
      ]
    }
  ],
  "condition": [
    {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "26929004",
          "display": "Alzheimer's Disease (Disorder)"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "G30",
          "display": "Alzheimer's disease"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "10001896",
          "display": "Alzheimer's disease"
        }
      ]
    }
  ],
  "contact": [
    {
      "name": "Bob James, Ph.D.",
      "telecom": [
        {
          "system": "phone",
          "value": "555-555-5555",
          "use": "work"
        }
      ]
    }
  ],
  "relatedArtifact": [
    {
      "type": "documentation",
      "label": "Protocol H2Q-MC-LZZT(c)",
      "url": "https://clinicaltrials.gov/show/NCTA12313212/Lzzt_protocol_redacted.pdf"
    }
  ],
  "keyword": [
    {
      "coding": [
        {
          "system": "https://id.nlm.nih.gov/mesh",
          "code": "D018721"
        }
      ],
      "text": "Selective M1 muscarinic agonists"
    }
  ],
  "description": "# Xanomeline (LY246708)\n# Protocol H2Q-MC-LZZT(c) \nSafety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease",
  "sponsor": {
    "reference": "Organization/EliLillyAndCompany"
  },
  "principalInvestigator": {
    "reference": "Practitioner/SamGetWell"
  },
  "arm": [
    {
      "name": "Placebo",
      "type": {
        "coding": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C49648"
          }
        ]
      },
      "description": "Placebo arm"
    },
    {
      "name": "Low-dose xanomeline arm",
      "type": {
        "coding": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C174266"
          }
        ]
      },
      "description": "Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)"
    },
    {
      "name": "High-dose xanomeline arm",
      "type": {
        "coding": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C174266"
          }
        ]
      },
      "description": "High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)"
    }
  ],
  "objective": [
    {
      "name": "To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",
      "type": {
        "coding": [
          {
            "code": "primary"
          }
        ]
      }
    },
    {
      "name": "To document the safety profile of the xanomeline TTS.",
      "type": {
        "coding": [
          {
            "code": "primary"
          }
        ]
      }
    },
    {
      "name": "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.",
      "type": {
        "coding": [
          {
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.",
      "type": {
        "coding": [
          {
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment.",
      "type": {
        "coding": [
          {
            "code": "secondary"
          }
        ]
      }
    },
    {
      "name": "To assess the treatment response as a function of Apo E genotype.",
      "type": {
        "coding": [
          {
            "code": "secondary"
          }
        ]
      }
    }
  ]
}